[Clinical effect of recombinant human granulocyte colony-stimulating factor on aplastic anemia].
The effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on neutropenia was studied in 30 patients with aplastic anemia (AA). RhG-CSF was administered intravenously daily at a dose of 2, 5, 10, or 20 micrograms/kg/day for more than 7 days. In the patients whose absolute neutrophil counts (ANC) were more than 0.1 X 10(9)/l, the rhG-CSF injections at greater than or equal to 5 micrograms/kg/day caused rapid and selective elevation of ANC which maintained during the injection period. Most of the patients were well tolerated, and minor side effects were observed in only 3 patients. These findings suggest that daily injections of rhG-CSF at a dose of greater than or equal to 5 micrograms/kg/day may be an effective strategy for the treatment of bacterial and/or fungal infections in AA patients.
Asano
S
S
Department of Hematology-Oncology, Institute of Medical Science, University of Tokyo.
Hirashima
K
K
Yoshida
Y
Y
Takaku
F
F
Miyazaki
T
T
Omine
M
M
Furusawa
S
S
Abe
T
T
Mori
M
M
Arimori
S
S
D000328:Adult; D000741:Anemia, Aplastic / Q000097:blood / Q000628:therapy*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007564:Japan; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000097:blood / Q000628:therapy; D009504:Neutrophils; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor